# Hidradenitis Suppurativa Phase 2b Study of Izokibep

> **NCT05355805** · PHASE2 · COMPLETED · sponsor: **ACELYRIN Inc.** · enrollment: 205 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Izokibep
- **DRUG:** Placebo to izokibep

## Key facts

- **NCT ID:** NCT05355805
- **Lead sponsor:** ACELYRIN Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-05
- **Primary completion:** 2023-08-02
- **Final completion:** 2024-02-21
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05355805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05355805, "Hidradenitis Suppurativa Phase 2b Study of Izokibep". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05355805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*